Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,011.12 -11.09 (-0.22%) Dow
37,775.38 +22.07 (+0.06%) Nasdaq
15,601.50 -81.87 (-0.52%) Bitcoin USD
63,572.21 +2,188.92 (+3.57%) CMC Crypto 200
1,312.62 +427.09 (+48.25%)
Ultragenyx Pharmaceutical Inc. (RARE)
After hours:
- Zacks
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
- GlobeNewswire
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Expansion Cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170 Additional long-term data in Dose-escalation Cohorts showed increasing and sustained clinical benefit through Day 758 Company will host investor call at 8:00 a.m. ET NOVATO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced new data from the Phase 1/2 study of GTX-102 for the
- GlobeNewswire
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link below NOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eas
